# Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)

> **NCT00496054** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 110 (actual)

## Conditions studied

- Gastroenteritis
- Rotavirus

## Interventions

- **BIOLOGICAL:** Rotavirus Vaccine, Live, Oral, Pentavalent

## Key facts

- **NCT ID:** NCT00496054
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00496054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00496054, "Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00496054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*